U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H37N5O2
Molecular Weight 451.6043
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CABERGOLINE

SMILES

CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(CC=C)C1

InChI

InChIKey=KORNTPPJEAJQIU-KJXAQDMKSA-N
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

HIDE SMILES / InChI
Molecular Formula C26H37N5O2
Molecular Weight 451.6043
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/dosage/cabergoline.html http://www.wikidoc.org/index.php/Cabergoline http://www.rxlist.com/dostinex-drug.htm

Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. It is FDA approved for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Common adverse reactions include constipation, nausea, dizziness, headache and fatigue. Cabergoline should not be administered concurrently with D-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.

CNS Activity

Originator

Approval Year

1996
224
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 1.5 nM [Ki]
Agonist
2752
 0.5 nM [Ki]
Agonist
2752
 1.2 nM [Ki]
Agonist
2752
 0.69 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
CABERGOLINE

Approved Use

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Launch Date

2005
Primary
Approved
8583
CABERGOLINE

Approved Use

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Launch Date

2005
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.3 ng/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
40.3 ng/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
67 ng/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1295 ng × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1884 ng × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2546 ng × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7883840
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
68.54 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7884663
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
REVIEW
https://pubmed.ncbi.nlm.nih.gov/12844325
unknown, unknown
 CABERGOLINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16367894
unhealthy, 41.0–73.5
Health Status: unhealthy
Age Group: 41.0–73.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16367894
Sources:
https://pubmed.ncbi.nlm.nih.gov/16367894
2 mg 1 times / day multiple, oral
Overdose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Other AEs: Cardiac valvulopathy...
Other AEs:
Cardiac valvulopathy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache (1.4%)
Nausea (0.9%)
Vomiting (0.9%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
1 mg 2 times / week multiple, oral
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Disc. AE: Pleural effusion, Pulmonary fibrosis...
Other AEs: Cardiac valvulopathy, Pericardial fibrosis...
AEs leading to
discontinuation/dose reduction:
Pleural effusion
Pulmonary fibrosis
Other AEs:
Cardiac valvulopathy
Pericardial fibrosis
Retroperitoneal fibrosis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Cardiac valvulopathy
2 mg 1 times / day multiple, oral
Overdose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Nausea 0.9%
Disc. AE
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Vomiting 0.9%
Disc. AE
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Headache 1.4%
Disc. AE
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Cardiac valvulopathy
1 mg 2 times / week multiple, oral
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Pericardial fibrosis
1 mg 2 times / week multiple, oral
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Retroperitoneal fibrosis
1 mg 2 times / week multiple, oral
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Pleural effusion Disc. AE
1 mg 2 times / week multiple, oral
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Pulmonary fibrosis Disc. AE
1 mg 2 times / week multiple, oral
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1741
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1932
 likely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1946
 yes
yes (co-administration study)
Comment: n healthy male volunteers, the mean of Cmax and AUC of cabergoline increased around 2.7 times by coadministration of clarithromycin.
Page: -
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3286
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3286
ChemicalBook
CB0282495
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0282495
eMolecules
2727031
https://www.emolecules.com/cgi-bin/more?vid=2727031
MolPort
MolPort-003-845-557
https://www.molport.com/shop/molecule-link/MolPort-003-845-557
ZINC
ZINC000003800008
http://zinc15.docking.org/substances/ZINC000003800008
PubMed

PubMed

TitleDatePubMed
[Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
2003-03-28
Involvement of PI3'-K, mitogen-activated protein kinase and protein kinase B in the up-regulation of the expression of nNOSalpha and nNOSbeta splicing variants induced by PRL-receptor activation in GH3 cells.
2003-03
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
2003-03
Prolactinomas, dopamine agonists and headache: two case reports.
2003-03
Selective control of the estrous cycle of the dog through suppression of estrus and reduction of the length of anestrus.
2003-03
Radioimmunoassay of prolactin for the meerkat (Suricata suricatta), a cooperatively breeding carnivore.
2003-02-01
Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.
2003-02
[Efficacy of cabergoline in the treatment of macroprolactinoma].
2003-01-18
Accurate mass measurement at enhanced mass-resolution on a triple quadrupole mass-spectrometer for the identification of a reaction impurity and collisionally-induced fragment ions of cabergoline.
2003
Alopecia induced by dopamine agonists.
2002-12-24
Hyperprolactinemia in men: clinical and biochemical features and response to treatment.
2002-12-20
Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress.
2002-12-20
Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
2002-12
Dopamine agonist monotherapy in Parkinson's disease.
2002-11-30
Detecting dose-response using contrasts: asymptotic power and sample size determination for binomial data.
2002-11-30
Hyperprolactinemia: etiology, diagnosis, and management.
2002-11
Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.
2002-11
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.
2002-11
Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
2002-11
Effect of cabergoline on thyroid function in hyperprolactinaemia.
2002-11
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
2002-11
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002-11
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002-11
Pregnancy outcome after cabergoline treatment in early weeks of gestation.
2002-10-29
A practical synthesis of cabergoline.
2002-10-04
Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy.
2002-10
An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease.
2002-10
Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma.
2002-10
Use of the dopamine agonist cabergoline in the treatment of movement disorders.
2002-10
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
2002-10
Gateways to clinical trials.
2002-09-13
Antioxidant properties of cabergoline: inhibition of brain auto-oxidation and superoxide anion production of microglial cells in rats.
2002-09-13
Combination of two different dopamine agonists in the management of Parkinson's disease.
2002-09
Gateways to Clinical Trials.
2002-09
Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment.
2002-09
Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
2002-08-09
Pregnancy termination in the bitch and queen.
2002-08
The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals.
2002-07
Sleep attacks in patients taking dopamine agonists: review.
2002-06-22
SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks.
2002-06-11
Use of cabergoline to treat primary and secondary anestrus in dogs.
2002-06-01
[Novel pharmacologic therapies in acromegaly].
2002-05-12
Medical management of prolactin-secreting pituitary adenomas.
2002
[Use of dopamine agonists in the treatment of Parkinson's disease].
2002
Assessment of cabergoline as a reproductive inhibitor in coyotes (Canis latrans).
2002
DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease.
2002
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
2002
Control of fertility in the red fox (Vulpes vulpes): effect of a single oral dose of cabergoline in early pregnancy.
2002
Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
2001-08
Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.
2001-08
Patents

Patents

BE 888243
1
JP2007131542A
1
JP2007517067A
31
US4526892 A
1

Sample Use Guides

In Vivo Use Guide
The recommended dosage for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Dosage increases should not occur more rapidly than every 4 weeks.
Route of Administration: Oral
In Vitro Use Guide
Tert-butylhydroperoxide caused a 42+/-4% neuronal death, which was prevented by cabergoline (2 h before) in a concentration-dependent manner (EC(50): 1.24 microM).
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:45:54 GMT 2025
Edited
by admin
on Wed Apr 02 07:45:54 GMT 2025
Record UNII
LL60K9J05T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CABASER
Preferred Name English
CABERGOLINE
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
FCE-21336
Code English
DOSTINEX
Brand Name English
CABERGOLINE [JAN]
Common Name English
CABERGOLINE [VANDF]
Common Name English
VELACTIS
Brand Name English
Cabergoline [WHO-DD]
Common Name English
CABERGOLINE [USP-RS]
Common Name English
ERGOLINE-8.BETA.-CARBOXAMIDE, N-(3-(DIMETHYLAMINO)PROPYL)-N-((ETHYLAMINO)CARBONYL)-6-(2-PROPENYL)-
Systematic Name English
CABERGOLINE [ORANGE BOOK]
Common Name English
FCE 21336
Code English
CABERGOLINE [USAN]
Common Name English
1-[(6-Allylergolin-8?-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
Systematic Name English
CABERGOLINE [EP MONOGRAPH]
Common Name English
cabergoline [INN]
Common Name English
CABERGOLINE [MI]
Common Name English
CABERGOLINE [MART.]
Common Name English
CABERGOLINE [USP MONOGRAPH]
Common Name English
CABERGOLINE [EMA EPAR VETERINARY]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
NCI_THESAURUS C38149
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
WHO-VATC QG02CB03
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
WHO-ATC N04BC06
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
NDF-RT N0000007618
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
LIVERTOX 135
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
WHO-VATC QN04BC06
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
NDF-RT N0000175827
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
WHO-ATC G02CB03
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
NDF-RT N0000007618
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
EMA VETERINARY ASSESSMENT REPORTS VELACTIS [SUSPENDED]
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL1201087
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
DRUG CENTRAL
460
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
MESH
C047047
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
WIKIPEDIA
CABERGOLINE
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
CAS
81409-90-7
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
IUPHAR
37
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
NCI_THESAURUS
C47428
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
INN
5860
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
SMS_ID
100000092143
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
USAN
II-10
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
EPA CompTox
DTXSID6022719
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
RXCUI
47579
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY RxNorm
CHEBI
3286
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
RS_ITEM_NUM
1084306
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
PUBCHEM
54746
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
LACTMED
Cabergoline
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
EVMPD
SUB06041MIG
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
DRUG BANK
DB00248
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
DAILYMED
LL60K9J05T
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
FDA UNII
LL60K9J05T
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY
MERCK INDEX
m2876
Created by admin on Wed Apr 02 07:45:54 GMT 2025 , Edited by admin on Wed Apr 02 07:45:54 GMT 2025
PRIMARY Merck Index
Related Record Type Details
Structure of CABERGOLINE DIPHOSPHATE
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
D(2) DOPAMINE RECEPTOR
TARGET -> AGONIST
Structure of CABERGOLINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Structure of CABERGOLINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
Structure of N-(3-(DIMETHYLAMINO)PROPYL)-6-(2-PROPENYL)-ERGOLINE-8-CARBOXAMIDE, (8.BETA.)-
METABOLITE -> PARENT
7% in urine
MINOR
URINE
Structure of 6-ALLYL-8.BETA.-CARBOXYERGOLINE
METABOLITE -> PARENT
41% in urine
MAJOR
URINE
Related Record Type Details
Structure of 6-ALLYL-8.BETA.-CARBOXYERGOLINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N8-(3-(DIMETHYLAMINO)PROPYL)-N1-ETHYL-6-(2-PROPENYL)-ERGOLINE-1,8-DICARBOXAMIDE, (8.BETA.)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-nitroso-desmethyl-cabergoline
IMPURITY -> PARENT
Structure of N-(3-(DIMETHYLAMINO)PROPYL)-6-(2-PROPENYL)-ERGOLINE-8-CARBOXAMIDE, (8.BETA.)-
IMPURITY -> PARENT
Structure of N8-(3-(DIMETHYLAMINO)PROPYL)-N1-ETHYL-6-(2-PROPENYL)-ERGOLINE-1,8-DICARBOXAMIDE, (8.BETA.)-
IMPURITY -> PARENT
Structure of 6-ALLYL-8.BETA.-CARBOXYERGOLINE
IMPURITY -> PARENT
Structure of ERGOLINE-1,8-DICARBOXAMIDE, N8-(3-(DIMETHYLAMINO)PROPYL)-N1-ETHYL-N8-((ETHYLAMINO)CARBONYL)-6-(2-PROPENYL)-, (8.BETA.)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-(3-(DIMETHYLAMINO)PROPYL)-6-(2-PROPENYL)-ERGOLINE-8-CARBOXAMIDE, (8.BETA.)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of CABERGOLINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966